Medicure Inc. (MCUJF)
| Market Cap | 18.86M +88.7% |
| Revenue (ttm) | 22.59M +38.3% |
| Net Income | -5.25M |
| EPS | -0.51 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,100 |
| Open | 1.800 |
| Previous Close | 1.790 |
| Day's Range | 1.800 - 1.820 |
| 52-Week Range | 0.675 - 1.880 |
| Beta | 1.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 23, 2026 |
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological i... [Read more]
Financial Performance
In 2025, Medicure's revenue was 28.86 million, an increase of 31.72% compared to the previous year's 21.91 million. Losses were -7.10 million, 583.1% more than in 2024.
Financial numbers in CAD Financial StatementsNews
Medicure Earnings Call Transcript: Q2 2026
Net revenue rose to CAD 7.4 million, driven by ZYPITAMAG and pharmacy acquisitions, but net loss widened to CAD 1.4 million due to a rebate liability and R&D spend. Adjusted EBITDA turned positive, and MC-1 phase III trial and new chemical entity development are progressing.
Medicure Registration statement: Q2 2026
Medicure filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Medicure Registration statement: Q2 2026
Medicure filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Medicure Earnings release: Q2 2026
Medicure released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / August 14, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals...
Medicure Announces CFO Change
WINNIPEG, MB / ACCESS Newswire / July 3, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure Earnings Call Transcript: Q1 2026
Revenue grew 44% year-over-year to CAD 7.9 million, driven by ZYPITAMAG and pharmacy acquisitions, while net loss narrowed. MC-1 phase III trial progresses, with potential for a lucrative FDA priority review voucher if approved.
Medicure Registration statement: Q1 2026
Medicure filed a registration statement on May 25, 2026, providing details about a securities offering with the SEC.
Medicure Registration statement: Q1 2026
Medicure filed a registration statement on May 25, 2026, providing details about a securities offering with the SEC.
Medicure Earnings release: Q1 2026
Medicure released its Q1 2026 earnings on May 25, 2026, summarizing the period's financial results.
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and hea...
Medicure Announces AGM Results and Appointment of New Director
WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and hea...
Medicure Slides: Investor presentation
Medicure has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Medicure Earnings Call Transcript: Q4 2025
Net revenue rose to CAD 28.9 million in 2025, driven by pharmacy acquisitions and Marley Drug growth, but net loss widened to CAD 7.1 million due to a CMS rebate, R&D, and amortization. AGGRASTAT faced generic pressure, while ZYPITAMAG excelled via Marley Drug.
Medicure Earnings release: Q4 2025
Medicure released its Q4 2025 earnings on April 27, 2026, summarizing the period's financial results.
Medicure Registration statement: Q4 2025
Medicure filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Medicure Registration statement: Q4 2025
Medicure filed a registration statement on April 27, 2026, providing details about a securities offering with the SEC.
Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
WINNIPEG, MB / ACCESS Newswire / April 23, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and h...
Medicure Announces Resignation of President and Chief Operating Officer
WINNIPEG, MB / ACCESS Newswire / April 17, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and h...
Medicure Earnings Call Transcript: Q3 2025
Q3 2025 net revenue rose 58% year-over-year to CAD 8.2 million, driven by pharmacy acquisitions and Zypitamag growth, but net loss was CAD 1.4 million due to lower Aggrastat sales and higher costs. MC-1 phase III trial and new chemical entity development remain key priorities.
Medicure Earnings release: Q3 2025
Medicure released its Q3 2025 earnings on November 20, 2025, summarizing the period's financial results.
Medicure Registration statement: Q3 2025
Medicure filed a registration statement on November 20, 2025, providing details about a securities offering with the SEC.
Medicure Registration statement: Q3 2025
Medicure filed a registration statement on November 20, 2025, providing details about a securities offering with the SEC.
Medicure Reports Financial Results for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 19, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals an...
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
WINNIPEG, MB / ACCESS Newswire / November 13, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceutica...